Chronic Myeloid Leukemia – Epidemiology – Emerging Markets Data
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CML for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.
Clarivate Epidemiology’s CML forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with CML per year?
How will improvements in survival change the number of people diagnosed with CML per year?
Of all people diagnosed with CML, how many in each country are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CML over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least 10 years of forecast data for the following CML patient populations:
Diagnosed incident cases of CML.
Diagnosed incident cases of CML by phase distribution.
Chronic Myeloid Leukemia - Epidemiology - Emerging Markets Data
Introduction
Key Findings
Overview
Patient Flow Diagram of CML Patients Across the Countries Under Study in 2017
Incidence of Chronic Myeloid Leukemia per 100,000 per Year Among People of All Ages in 2017 and 2027ttttttttt
Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Chronic Myeloid Leukemia over the Next Ten Yearstttttttt
Prevalence of Chronic Myeloid Leukemia per 100,000 per year Among People of All Ages in 2017 and 2027ttttt
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Chronic Myeloid Leukemia over the Next Ten Yearstttttttt
Analysis of the Prevalent Cases of Chronic Myeloid Leukemia in 2017 by Drug-Treated Statusttttttt
Epidemiology Data
Methods
Newly Diagnosed Incidence
Phase at Diagnosis
Diagnosed Prevalence
Drug-Treated Prevalence
Drug-Treatable Populations
Cytogenetics
Progression Events
Reference Materials
Literature Review
Studies Included in the Analysis of Chronic Myeloid Leukemia
Studies Excluded from the Analysis of Chronic Myeloid Leukemia
Risk/Protective Factors
Risk/Protective Factors for Chronic Myeloid Leukemia
Bibliography
Narendra Parihar
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
